Induced Pluripotent Stem Cells Market (2026 - 2033)

Induced Pluripotent Stem Cells Market Summary

Market Dynamics

The induced pluripotent stem cells (iPSC) market is experiencing strong growth, driven by increasing adoption in disease modeling, drug discovery, toxicity testing, and personalized medicine research. Rising investments in stem cell research, expanding biopharmaceutical R&D activities, and growing collaborations between academic institutions and industry participants are supporting market expansion. Moreover, continuous technological advancements in cell reprogramming and characterization, along with increasing demand for advanced human cell-based models in preclinical research, are expected to sustain market growth over the forecast period.

Market Concentration & Characteristics

The induced pluripotent stem cells (iPSC) industry is characterized by a high degree of innovation, driven by continuous advancements in cell reprogramming technologies, genome editing, and scalable manufacturing processes. Innovations in generating clinical-grade, GMP-compliant iPSCs are accelerating their translational and therapeutic applications. For instance, in July 2024, Accelerated Biosciences and Pluristyx successfully developed clinical-grade iPSC lines from human trophoblast stem cells using proprietary mRNA reprogramming technology, highlighting ongoing progress in the development of high-quality stem cell platforms for regenerative medicine and advanced research.

The induced pluripotent stem cells industry is witnessing a moderate to high level of strategic partnerships and collaborations as companies aim to advance cell therapy platforms, enhance manufacturing capabilities, and accelerate clinical development. For instance, in September 2023, Eterna Therapeutics partnered with Lineage Cell Therapeutics to initiate the development of a hypoimmune iPSC line for neurology indications, strengthening efforts to develop immune-evasive, off-the-shelf cell therapies and supporting innovation in the iPSC market.

The regulatory impact on the induced pluripotent stem cells industry is significant. Regulatory authorities are focusing on establishing stringent guidelines for biosafety, contamination control, cell line authentication, and other factors. This compliance with regulatory standards represents significant challenges that may limit the growth of the market

The induced pluripotent stem cells market has witnessed moderate product expansion, driven by continuous advancements in iPSC-derived cell products, culture systems, and research tools. For instance, in September 2024, FUJIFILM Cellular Dynamics commercially launched its iCell Sensory Neurons, a human iPSC-derived cell model designed to support pain research, neuroscience, and drug discovery, thereby expanding its portfolio of iPSC-based research products.

The induced pluripotent stem cells market is witnessing a high level of regional expansion, indicating rapid growth and increasing market presence across different geographic regions. This expansion is driven by several factors, including the increased research and development focused on iPSCs for regenerative medicine, disease modeling, and drug discovery.

Analyst Perspective

The induced pluripotent stem cells (iPSC) market is expected to witness strong growth, driven by increasing applications in regenerative medicine, disease modeling, drug discovery, and cell & gene therapy research. Rising investments in stem cell research, expanding clinical development activities, and growing demand for patient-specific disease models are accelerating market expansion. Continuous advancements in iPSC reprogramming, differentiation, and genome editing technologies are improving research efficiency and therapeutic potential. As precision medicine gains momentum, market participants are focusing on scalable manufacturing, strategic collaborations, and innovative iPSC-based platforms to strengthen their competitive position and support long-term market growth.

Derived Cell Type Insights

The fibroblasts segment held the largest market share of 30.5% in 2025, owing to their high accessibility, robust reprogramming efficiency, and extensive use in induced pluripotent stem cell (iPSC) generation. Fibroblast-derived iPSCs are widely utilized in disease modeling, drug discovery, regenerative medicine, and cell therapy research. In addition, their therapeutic potential in wound healing and skin regeneration, supported by ongoing preclinical and translational research, is expected to continue driving segment growth.

The hepatocytes segment is expected to register the fastest CAGR over the forecast period, driven by the increasing adoption of iPSC-derived hepatocytes in drug discovery, hepatotoxicity testing, disease modeling, and regenerative medicine. Growing demand for physiologically relevant human liver models in pharmaceutical research, coupled with advancements in iPSC differentiation technologies, is expected to further support segment growth.

Application Insights

The drug development segment held the largest market share of 48.9% in 2025, owing to the global adoption of induced pluripotent stem cells (iPSCs) in disease modeling, target identification, drug screening, and toxicity assessment. iPSC-derived human cell models provide physiologically relevant platforms that improve preclinical drug evaluation, reduce reliance on animal models, and support the development of precision medicines, thereby driving segment growth.

The tissue engineering & regenerative medicine segment is expected to register a significant CAGR over the forecast period. driven by the increasing use of induced pluripotent stem cells (iPSCs) for tissue regeneration, cell replacement therapies, and personalized medicine. Their ability to differentiate into multiple cell types and generate patient-specific, immunocompatible tissues support applications in treating degenerative diseases and is expected to drive segment growth.

End use Insights

The pharmaceutical & biotechnology companies segment dominated the market with a share of 59.9% in 2025, owing to increasing investments in stem cell research, expanding R&D expenditure, and the growing integration of iPSC platforms into preclinical development workflows. The rising focus on accelerating therapeutic development, improving predictive drug evaluation, and strengthening cell therapy pipelines has further contributed to the segment's leading market position.

The academic & research institutes segment is projected to witness the fastest over the forecast period, owing to increasing government and institutional funding for stem cell research, expanding collaborative research programs, and growing efforts to advance fundamental studies in developmental biology and disease mechanisms. The rising establishment of dedicated stem cell research centers and increasing availability of research grants are further expected to drive segment growth.

Regional Insights

North America dominated the induced pluripotent stem cells industry, accounting for the largest revenue share of 35.8% in 2025, owing to the presence of a well-established regenerative medicine ecosystem, strong research funding, and increasing clinical translation of iPSC-based therapies. For instance, in May 2024, the California Institute for Regenerative Medicine (CIRM) awarded USD 53 million to support multiple clinical and translational stem cell research projects, including iPSC-based therapeutic programs, further strengthening regenerative medicine research and accelerating the development of iPSC-based therapies across the region.

U.S.Induced Pluripotent Stem Cells Market Trends

induced pluripotent stem cells industry in the U.S. is expected to grow over the forecast period due to increasing clinical translation of iPSC-based therapies, favorable funding for regenerative medicine, and the presence of leading biotechnology companies engaged in cell therapy development.

Europe Induced Pluripotent Stem Cells Market Trends

The induced pluripotent stem cells market in Europe was identified as a lucrative region in this industry, owing to strong academic research capabilities, supportive regulatory frameworks for advanced therapy medicinal products (ATMPs), and increasing public-private collaborations focused on stem cell technologies.

The UK induced pluripotent stem cells market held a significant share, attributed to expanding investments in advanced cell therapies, increasing translational research, and the presence of leading academic institutions specializing in stem cell biology.

The Germany induced pluripotent stem cells market is anticipated to grow significantly over the forecast period, supported by its strong biotechnology sector, advanced research infrastructure, and increasing investments in regenerative medicine and cell therapy. For instance, in April 2024, Merck KGaA announced an investment of more than EUR 300 million in a new Life Science Research Center at its Darmstadt headquarters, strengthening research capabilities in next-generation biologics and advanced therapeutic technologies, including applications supporting induced pluripotent stem cell research.

Asia Pacific Induced Pluripotent Stem Cells Market Trends

Asia-Pacific induced pluripotent stem cells industry is expected to grow at the fastest CAGR of 14.2% during the forecast period, owing to increasing government support for regenerative medicine, growing investments in stem cell manufacturing, and rising collaborations between academia and industry across the region.

The China induced pluripotent stem cells market is expected to witness significant growth over the forecast period, driven by increasing investments in stem cell biobanking, expanding clinical research activities, and supportive government initiatives promoting regenerative medicine. Favorable regulatory and policy support for stem cell research has further supported market development. In addition, the Ministry of Science and Technology has established four national stem cell banks across eastern, southern, and northern China, strengthening the country's research infrastructure and supporting the advancement and commercialization of iPSC-based technologies.

The induced pluripotent stem cells market in Japan is witnessing rapid growth, driven by its leadership in iPSC research, supportive regulatory environment for regenerative medicine, and increasing clinical translation of iPSC-based therapies. For instance, in July 2024, Kyoto University's Center for iPS Cell Research and Application (CiRA) announced that its Phase II clinical trial of bosutinib, identified through iPSC-based drug repurposing, achieved its primary endpoints for the treatment of amyotrophic lateral sclerosis (ALS), reinforcing Japan's leadership in advancing iPSC-based therapeutic development.

Latin America Induced Pluripotent Stem Cells Market Trends

The Latin America induced pluripotent stem cells market is expected to witness gradual growth over the forecast period, driven by increasing investments in regenerative medicine, expanding stem cell research capabilities, and growing collaborations between research institutions and healthcare organizations. For instance, in March 2024, Brazil's Fundação Oswaldo Cruz (Fiocruz) and Caring Cross announced a collaboration to establish local manufacturing capabilities for CAR-T cell and stem cell gene therapies, strengthening the region's advanced cell therapy infrastructure and supporting future adoption of iPSC-based technologies.

MEA Induced Pluripotent Stem Cells Market Trends

The induced pluripotent stem cells industry in MEA is expected to witness steady growth, driven by increasing investments in precision medicine, gradual expansion of regenerative medicine research, and improving healthcare infrastructure supporting advanced cellular therapies.

Key Induced Pluripotent Stem Cells Company Insights

The induced pluripotent stem cells market is characterized by the presence of several established biotechnology companies focused on advancing stem cell technologies, regenerative medicine, and cell therapy development. Key players such as FUJIFILM Cellular Dynamics, Inc., REPROCELL Inc., STEMCELL Technologies Inc., Takara Bio, Inc., Evotec SE, and Fate Therapeutics, Inc. maintain a strong market presence through extensive iPSC product portfolios, continuous investments in research and development, and strategic collaborations. Companies are increasingly strengthening their competitive position by expanding clinical-grade iPSC manufacturing capabilities, developing specialized cell models, and accelerating the commercialization of iPSC-based research tools and therapeutic platforms. 

Key Induced Pluripotent Stem Cells Companies:

The following key companies have been profiled for this study on the induced pluripotent stem cells market.

• REPROCELL Inc.

• STEMCELL Technologies Inc.

• Cellular Engineering Technologies Inc.

• Takara Bio, Inc.

• Axol Bioscience Ltd.

• Fate Therapeutics, Inc.

• FUJIFILM Cellular Dynamics, Inc.

• Cynata Therapeutics Limited

• Evotec SE

• Astellas Pharma Inc.

Competitive Benchmarking

Recent Developments

• In July 2026, RoosterBio and Applied StemCell established a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions by integrating GMP-compatible iPSC technologies with advanced media systems and manufacturing expertise, supporting efficient development and production of advanced cell therapies.

• In July 2026, STEMCELL Technologies and CCRM partnered to expand access to matched GMP and RUO induced pluripotent stem cell (iPSC) lines for cell therapy development, enhancing availability of standardized cellular resources and supporting advancement of scalable regenerative medicine applications.

• In May 2026, FUJIFILM Cellular Dynamics, Inc. launched a new induced pluripotent stem cell (iPSC) development and manufacturing facility in Madison, Wisconsin, expanding its production capacity and capabilities to support research-grade iPSC products, cell therapy development, and next-generation regenerative medicine applications.

Induced Pluripotent Stem Cells Market Report Scope

Global Induced Pluripotent Stem Cells Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global induced pluripotent stem cells market on the basis of derived cell type, application, end use, and region:

• Derived Cell Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Hepatocytes

  • Fibroblasts

  • Keratinocytes

  • Amniotic Cells

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug Development

  • Tissue Engineering & Regenerative Medicine

    • Neurology

    • Orthopedics

    • Oncology

    • Cardiovascular and Myocardial Infraction

    • Diabetes

    • Others

  • Toxicology Research

  • Disease Modeling

• End use Outlook (Revenue, USD Million, 2021 - 2033)

  • Academic & Research Institutes

  • Pharmaceutical & Biotechnology Companies

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The induced pluripotent stem cells market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each induced pluripotent stem cells segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations